Brain tumour clinical trial title

CMS Study – Cerebellar Mutism Syndrome in children with brain tumours of the posterior fossa (Study ID: 31760)

Brain tumour type




Central nervous system (CNS) tumours constitute 25% of all childhood cancers, and more than half of these are located in the cerebellum. One of the most troublesome late effects after operation for such a tumour is the cerebellar mutism syndrome (CMS) which is seen in up to 25% of children after surgery. It is characterized by mutism, hypotonia, ataxia and irritability, and the exact causes have yet to be identified. The purposes of this study are to uncover: 1) which surgical methods are least likely to cause the CMS and if there is a difference in risk between primary surgery and re-operation, 2) which patients may be genetically predisposed to developing the CMS, 3) the effect of corticosteroids, and 4) differences in incidence and clinical course of the CMS according to tumour type, comorbidities, handedness and treatments. We hope that the results will contribute to an overall reduction in incidence of the CMS and lead to international harmonization of the treatment of these patients.

Date added: 12th January 2019

Open/Closed: Open

Trial ends: December 2018


Alder Hey CHildren's NHS Foundation Trust

Contact details

Claire Cummings :
Eaton Road

L12 2AP

Find on Google maps »